KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Return on Capital Employed for 10 consecutive years, with 0.32% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 10.0% to 0.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32% through Dec 2025, down 10.0% year-over-year, with the annual reading at 0.32% for FY2025, 10.0% down from the prior year.
  • Return on Capital Employed hit 0.32% in Q4 2025 for CRISPR Therapeutics AG, down from 0.28% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.19% in Q2 2021 to a low of 0.32% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 0.15% across 5 years, with a median of 0.22% in 2021.
  • Biggest five-year swings in Return on Capital Employed: surged 37bps in 2021 and later crashed -45bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.14% in 2021, then tumbled by -321bps to 0.31% in 2022, then soared by 65bps to 0.11% in 2023, then tumbled by -99bps to 0.22% in 2024, then crashed by -46bps to 0.32% in 2025.
  • Business Quant data shows Return on Capital Employed for CRSP at 0.32% in Q4 2025, 0.28% in Q3 2025, and 0.28% in Q2 2025.